dc.contributor.author
Montes Moreno, Santiago
dc.contributor.author
Batlle, Ana
dc.contributor.author
González de Villambrosía, Sonia
dc.contributor.author
Sánchez-Espiridión, Beatriz
dc.contributor.author
Cereceda, Laura
dc.contributor.author
González Barca, Eva
dc.contributor.author
Purroy, Noelia
dc.contributor.author
Pardal, Emilia
dc.contributor.author
Martín, Alejandro
dc.contributor.author
Grande, Carlos
dc.contributor.author
Mazorra, Francisco
dc.contributor.author
Insunza, Andrés
dc.contributor.author
Quero, Cristina
dc.contributor.author
Aguiar Bujanda, David
dc.contributor.author
Cruz, Miguel Ángel
dc.contributor.author
Rueda Dominguez, Antonio
dc.contributor.author
Llanos, Marta
dc.contributor.author
Gómez Codina, Jose
dc.contributor.author
García Arroyo, Francisco Ramón
dc.contributor.author
Caballero, Dolores
dc.contributor.author
Conde, Eulogio
dc.contributor.author
López, Andres
dc.contributor.author
Provencio, Mariano
dc.contributor.author
Piris, Miguel A.
dc.date.issued
2020-11-30T15:34:05Z
dc.date.issued
2020-11-30T15:34:05Z
dc.date.issued
2014-08-01
dc.date.issued
2020-11-30T15:34:05Z
dc.identifier
https://hdl.handle.net/2445/172406
dc.description.abstract
Diffuse large B-cell lymphoma (DLBCL) is a highly heterogeneous disease entity. Young patients with high-intermediate and high aa-IPI score seem to be good candidates to receive alternative treatments to standard RCHOP-21 including EPOCH-R,2 R-ACVBP+HDT-ASCT3 and upfront autologous stem cell transplantation. Other risk factors can be used to identify patients for the use of more doseintense regimens including bulky disease, interim PET positivity and, importantly, molecular profiles.
dc.format
application/pdf
dc.publisher
Ferrata Storti Foundation
dc.relation
Reproducció del document publicat a: https://doi.org/10.3324/haematol.2014.104976
dc.relation
Haematologica, 2014, vol. 99, num. 8, p. 138-141
dc.relation
https://doi.org/10.3324/haematol.2014.104976
dc.rights
(c) Ferrata Storti Foundation, 2014
dc.rights
info:eu-repo/semantics/openAccess
dc.source
Articles publicats en revistes (Ciències Clíniques)
dc.subject
Cèl·lules mare
dc.title
Risk adapted high-dose and dose-dense therapies modulate the impact of biological classification in diffuse large B-cell lymphoma prognosis
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion
